)
Shares of RPG Life Sciences have rallied 6% to Rs 156 on the National Stock Exchange after the promoter of the pharmaceutical company buying shares through open market.
The stock opened at Rs 150 and touched a record high of Rs 160 on the NSE. Till 1004 hours, a combined 379,698 shares changed hands against an average sub 500,000 shares that were traded daily in past two weeks on the NSE and BSE.
In past two-weeks, the stock rallied 49% from Rs 105 after Harsh Vardhan Goneka, trustee of Nucleus Life Trust, bought 277,165 equity shares representing 1.7% of total equity of RPG Life Sciences through open market. The CNX Nifty dipped 3.3% during the same period.
On March 26, Nucleus Life Trust had purchased 83,376 shares of RPG Life Sciences at an average price of Rs 142.47 per share on the NSE, the bulk deal data shows.
Earlier, between March 16 and March 18, Nucleus Life Trust acquired 189,789 shares of the company through BSE and NSE, RPG Life Sciences said in a regulatory filing.
As of December 2014, Harsh Vardhan Goneka and along with other promoters held 61.83% stake in RPG Life Sciences, the shareholding pattern data shows.
The stock opened at Rs 150 and touched a record high of Rs 160 on the NSE. Till 1004 hours, a combined 379,698 shares changed hands against an average sub 500,000 shares that were traded daily in past two weeks on the NSE and BSE.
In past two-weeks, the stock rallied 49% from Rs 105 after Harsh Vardhan Goneka, trustee of Nucleus Life Trust, bought 277,165 equity shares representing 1.7% of total equity of RPG Life Sciences through open market. The CNX Nifty dipped 3.3% during the same period.
On March 26, Nucleus Life Trust had purchased 83,376 shares of RPG Life Sciences at an average price of Rs 142.47 per share on the NSE, the bulk deal data shows.
Earlier, between March 16 and March 18, Nucleus Life Trust acquired 189,789 shares of the company through BSE and NSE, RPG Life Sciences said in a regulatory filing.
As of December 2014, Harsh Vardhan Goneka and along with other promoters held 61.83% stake in RPG Life Sciences, the shareholding pattern data shows.
